Luye Pharma Group Ltd.: Schizophrenia trials

The registry lists 13 Schizophrenia studies with Luye Pharma Group Ltd. as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 12Phase 2 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With SchizophreniaNot yet recruitingNCT07396870Phase 2
• A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020RecruitingNCT07230652Phase 1
• A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017Not yet recruitingNCT06980207Phase 1
• Effect of Food and Age on the Pharmacokinetics of LY03017Not yet recruitingNCT06793995Phase 1
• A Food Effect Study of LY03020 in Healthy SubjectsActive, not recruitingNCT07292233Phase 1
• A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy SubjectsCompletedNCT06556966Phase 1
• Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT05321602Phase 1
• Relative Bioavailability of LY03010 Compared to Listed DrugCompletedNCT04922593Phase 1
• Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia PatientsCompletedNCT04572685Phase 1
• A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia PatientsCompletedNCT03751488Phase 1
• An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT02186769Phase 1
• Bioavailability of LY03004 and Risperdal® Consta®CompletedNCT02091388Phase 1
• Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT02055287Phase 1